Search research articles
Contact Us
Filters
Showing results (81-90 of 148) with videos related to
Page
of 15
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 1, 2016
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial
N Harbeck, S Iyer, N Turner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 14, 2025
Redefining clinical trial strategic design to support drug approval in medical oncology
G Antonarelli, J M Pérez-García, M Gion, et al.
Breast Cancer Research and Treatment
|
February 22, 2023
Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL
M Thill, M-O Zahn, A Welt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2013
Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer
U Nitz, O Gluz, I Zuna, et al.
Geburtshilfe Und Frauenheilkunde
|
March 5, 2016
ABC3 Consensus Commented from the Perspective of the German Guidelines: Third International Consensus Conference for Advanced Breast Cancer (ABC3), Lisbon, 07. 11. 2015
M Untch, D Augustin, J Ettl, et al.
ESMO Real World Data and Digital Oncology
|
April 20, 2026
Unmet need for patients with metastatic triple-negative breast cancer initiating first-line treatment: data from the prospective German tumor registry OPAL
E Stickeler, T Decker, M-O Zahn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 16, 2013
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients
N Harbeck, M Schmitt, C Meisner, et al.
Breast Cancer Research and Treatment
|
February 24, 2019
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study
R Wuerstlein, R Kates, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 1, 2008
Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial
M Schmidt, A Victor, D Bratzel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2016
Research needs in breast cancer
F Cardoso, N Harbeck, C H Barrios, et al.
Page
of 15
Search research articles
Search
Showing results (81-90 of 148) with videos related to
Sort By:
Page
of 15
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 1, 2016
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial
N Harbeck, S Iyer, N Turner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 14, 2025
Redefining clinical trial strategic design to support drug approval in medical oncology
G Antonarelli, J M Pérez-García, M Gion, et al.
Breast Cancer Research and Treatment
|
February 22, 2023
Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL
M Thill, M-O Zahn, A Welt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2013
Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer
U Nitz, O Gluz, I Zuna, et al.
Geburtshilfe Und Frauenheilkunde
|
March 5, 2016
ABC3 Consensus Commented from the Perspective of the German Guidelines: Third International Consensus Conference for Advanced Breast Cancer (ABC3), Lisbon, 07. 11. 2015
M Untch, D Augustin, J Ettl, et al.
ESMO Real World Data and Digital Oncology
|
April 20, 2026
Unmet need for patients with metastatic triple-negative breast cancer initiating first-line treatment: data from the prospective German tumor registry OPAL
E Stickeler, T Decker, M-O Zahn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 16, 2013
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients
N Harbeck, M Schmitt, C Meisner, et al.
Breast Cancer Research and Treatment
|
February 24, 2019
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study
R Wuerstlein, R Kates, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 1, 2008
Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial
M Schmidt, A Victor, D Bratzel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2016
Research needs in breast cancer
F Cardoso, N Harbeck, C H Barrios, et al.
Page
of 15